Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Système rénine-angiotensine dysfonctionnel en cas de choc septique (MANTRA)

23 septembre 2026 mis à jour par: Wake Forest University Health Sciences

Despite best therapy efforts, sepsis and septic shock are associated with mortality rates of up to 40%. This clinical trial will determine the benefit of exogenous Angiotensin II versus norepinephrine (conventional care) treatment in septic shock patients. This trial will determine whether there are better predictors of septic shock severity. This approach may inform more appropriate treatment regimens and improve outcomes for these patients.

Aperçu de l'étude

Statut

Pas encore de recrutement

Les conditions

Description détaillée

This study will determine whether normalization of renin-angiotensin-aldosterone system (RAAS) signaling in sepsis occurs more rapidly with treatment with Angiotensin II compared with conventional vasopressors. Trial samples will be used to identify the best RAAS biomarker predictor of treatment response via in-depth longitudinal analysis of RAAS component and to determine the extent and mechanisms of Angiotensin II impact on innate immune function during sepsis. Successful accomplishment of our aims will provide the capability to improve endotyping of septic patients by establishing the most precise and robust measurement of renin (and RAAS dysfunction). This work will improve staging and clinical precision and will facilitate the criteria for therapeutic development of targets in septic shock.

Type d'étude

Interventionnel

Inscription (Estimé)

78

Phase

  • Phase 4

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

    • Massachusetts
      • Boston, Massachusetts, États-Unis, 02114
        • Massachusetts General Hospital-Harvard
        • Contact:
        • Contact:
        • Chercheur principal:
          • Michael R Filbin, MD, MS
        • Chercheur principal:
          • Daniel E Leisman, MD
        • Sous-enquêteur:
          • Marcia Goldberg, MD
        • Sous-enquêteur:
          • Kathryn Hibbert, MD
    • North Carolina
      • Winston-Salem, North Carolina, États-Unis, 27157
        • Atrium Health Wake Forest Baptist
        • Contact:
        • Contact:
        • Chercheur principal:
          • Ashish Khanna, MD
        • Sous-enquêteur:
          • Christopher Schaich, PhD
        • Sous-enquêteur:
          • Daniel C Files, MD
        • Chercheur principal:
          • Mark Chappell, PhD

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

- The presence of septic shock, defined by sepsis-3 criteria: 1-adult patients (18 years or older) with septic shock, defined by SEPSIS-3 criteria: a) suspected or known infection, b) hypotension requiring vasopressors, and c) lactate >2mmol/L 2-receiving either norepinephrine or phenylephrine with or without additional vasopressor support 3- total norepinephrine equivalent dose (NED) ≥0.1 mcg/kg/min and ≤0.5 mcg/kg/min, to maintain a MAP of at least 65 mmHg, is required for randomization 4-ability to consent and randomize within 24 hrs of first reaching NED threshold and within 48 hrs of hospital arrival

Exclusion Criteria:

  • Age <18 years
  • Prisoners
  • Pregnant women
  • Patients for whom urgent surgery is anticipated
  • Leukocyte count <1,000 cells/μL
  • Absolute monocyte count <200 cells/μL
  • Bone marrow transplant within the past 30 days
  • Patients that will be withdrawing aggressive resuscitation, including withdraw of vasopressor support
  • transfer from outside ICU
  • history of liver cirrhosis with Child-Pugh score ≥6

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Angiotensin II

Continuous infusion of Angiotensin II for up to 48 hours

randomized to receive Angiotensin II continuous infusion for up to 48 hours

Comparateur actif: Norepinephrine

Continuous infusion of Norepinephrine for up to 48 hours

randomized to receive Norepinephrine continuous infusion for up to 48 hours

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Mean Renin Level - Hour 24
Délai: Hour 24

Mean plasma renin level (PRA) as a measure of renin-angiotensin-aldosterone system restoration. Normal levels of active renin <1.1 pM (40 pg/mL). A level higher than normal can indicate level of shock.

Hour 24

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Norepinephrine Equivalent Dose Requirement (NEE)
Délai: Baseline, Hour 3, Hour 12, Hour 24, Hour 48, Hour 72

NEE indicates severity of shock and need for vasopressors to support blood pressure. Normal range is 0.0-1.0 mcg/kg/min. Levels above normal indicate shock and need for vasopressors. The higher the level the more severe.

Baseline, Hour 3, Hour 12, Hour 24, Hour 48, Hour 72
Number of Days Without Renal Replacement Therapy
Délai: Day 28

Number of days without renal replacement therapy

Day 28
Number of Days of Vasopressor Use
Délai: Day 28

Number of days without vasopressor use

Day 28
Number of Days Without Mechanical Ventilation
Délai: Day 28

Number of days without invasive mechanical ventilation

Day 28
Number of Hours Vasopressor Free
Délai: Hour 72

Number of hours without requiring vasopressors during first 72 hours after randomization

Hour 72
Number of Hours Alive
Délai: Hour 72

Number of hours alive during first 72 hours after randomization

Hour 72
Number of Days Alive
Délai: Day 28

Number of days alive

Day 28
Mean Renin Level
Délai: Baseline, Hour 3, Hour 12, Hour 48, Hour 72

Mean renin level as a measure of renin-angiotensin-aldosterone system restoration. Normal levels of active renin <1.1 pM (40 pg/mL). A level higher than normal can indicate level of shock.

Baseline, Hour 3, Hour 12, Hour 48, Hour 72
Sequential Organ Failure Assessment (SOFA) Score
Délai: Baseline, Hour 24, Hour 48

SOFA score indicates the number and severity of failed organs and provides prognostic information on in-hospital survival in patients with severe sepsis and septic shock. Score above 0 indicates organ failure. The higher the score the more failed organs and degree of organ failure.

Baseline, Hour 24, Hour 48
APACHE-II Score
Délai: Baseline, Hour 24, Hour 48

APACHE-II score assesses severity of illness in critically ill patients and indicates risk of mortality. Score range 0-10 low risk of mortality, 11-20 moderate risk, 21-30 high risk, 31 or above very high risk.

Baseline, Hour 24, Hour 48
Lactate Level
Délai: Baseline, Hour 3, Hour 12, Hour 24, Hour 48, Hour 72

Lactate is an indicator of sepsis severity. Levels 2.3-20 mmol/L indicate sepsis. The higher the score the more severe.

Baseline, Hour 3, Hour 12, Hour 24, Hour 48, Hour 72
Kidney Disease Improving Global Outcomes (KDIGO) Stage
Délai: Baseline, Hour 24, Hour 48

Participant stage of acute kidney injury will be determined as follows Stage 1: Increase in serum creatinine ≥ 0.3 mg/dL in 48 hours or 1.5 to 1.9 multiplied by baseline (in 7 days); Stage 2: 2.0 to 2.9 multiplied by baseline serum creatinine; Stage 3: 3.0 or more multiplied by baseline; increase in serum creatinine ≥ 4.0 mg/dL; or beginning of renal replacement therapy regardless of a previous KDIGO stage. Higher stage indicates higher severity of renal failure.

Baseline, Hour 24, Hour 48
Creatinine Level
Délai: Baseline, Hour 24, Hour 48

Creatinine level is an indicator of renal disease severity. Normal range for women 0.7-1.3 mg/dL, men 0.6-1.1 mg/dL. Levels higher than normal indicate renal disease. The higher the level the more severe.

Baseline, Hour 24, Hour 48
BUN Level
Délai: Baseline, Hour 24, Hour 48

BUN level is an indicator of renal disease severity. Levels above 24 mg/dL indicate renal disease. The higher the level the more severe.

Baseline, Hour 24, Hour 48
Bicarbonate Level
Délai: Baseline, Hour 24, Hour 48

Bicarbonate level is an indicator of acid base disturbance severity. Normal range is 22-29 mEq/L. Levels above or below the normal range indicate acid base disturbance. The higher the score the more severe.

Baseline, Hour 24, Hour 48
Number of Participants with Acute Respiratory Distress Syndrome (ARDS)
Délai: Baseline, Hour 24, Hour 48

Number of participants with ARDS

Baseline, Hour 24, Hour 48
SpO2/FiO2 Ratio Level
Délai: Baseline, Hour 24, Hour 48

SpO2/FiO2 ratio level is an indicator of lung injury severity. Mild severity 315-235, moderate severity 148-235, severe <148.

Baseline, Hour 24, Hour 48
PaO2/FiO2 Ratio Level
Délai: Baseline, Hour 24, Hour 48

PaO2/FiO2 ratio level is an indicator of lung injury severity. Mild severity 201-300 mmHg; moderate severity 101-200 mmHg, severe ≤ 100 mmHg.

Baseline, Hour 24, Hour 48
Serum Aspartate Aminotransferases Level
Délai: Baseline, Hour 24, Hour 48

Serum aspartate aminotransferases level is an indicator of liver injury severity. Normal range 8-48 U/L. Levels above normal indicate livery injury. The higher the level the more severe.

Baseline, Hour 24, Hour 48
Alanine Aminotransferases Level
Délai: Baseline, Hour 24, Hour 48

Alanine aminotransferases level is indicator of liver injury severity. Normal range 7-55 U/L. Levels higher than normal indicate liver injury. The higher the level the more severe.

Baseline, Hour 24, Hour 48
Alkaline Phosphatase Level
Délai: Baseline, Hour 24, Hour 48

Alkaline phosphatase level is an indicator of liver injury severity. Normal range 40-129 U/L. Levels higher than normal indicate liver injury. The higher the level the more severe.

Baseline, Hour 24, Hour 48
Bilirubin Level
Délai: Baseline, Hour 24, Hour 48

Bilirubin level is an indicator of liver injury severity. Normal range 0.1-1.2 mg/dL. Levels higher than normal indicate liver injury. The higher the liver the more severe.

Baseline, Hour 24, Hour 48
Albumin Level
Délai: Baseline, Hour 24, Hour 48

Albumin level is an indicator of liver injury severity. Normal range 3.5-5.0 g/dL. Levels higher than normal indicate liver injury. The higher the level the more severe.

Baseline, Hour 24, Hour 48
Troponin I Level
Délai: Baseline, Hour 24, Hour 48

Troponin I level is an indicator of cardiac myocyte injury. Normal range 0-0.04 ng/mL. Levels higher than normal indicate cardiac myocyte injury. The higher the level the more severe.

Baseline, Hour 24, Hour 48
Troponin T Level
Délai: Baseline, Hour 24, Hour 48

Troponin T level is an indicator of cardiac myocyte injury. Normal range 0-0.01 ng/mL. Levels higher than normal indicate cardiac myocyte injury. The higher the level the more severe.

Baseline, Hour 24, Hour 48
Neutrophil Gelatinase-Associated Lipocalin Serum Level
Délai: Baseline, Hour 24, Hour 48

Neutrophil gelatinase-associated lipocalin serum level indicates risk of kidney injury. Normal serum level is <10 mcg/L. Levels higher than normal indicate risk of kidney injury.

Baseline, Hour 24, Hour 48
Neutrophil Gelatinase-Associated Lipocalin Urine Level
Délai: Baseline, Hour 24, Hour 48

Neutrophil gelatinase-associated lipocalin urine level indicates risk of kidney injury. Normal urine level is ≤50 ng/ml. Risk of kidney disease: Low risk 51-149 ng/ml, moderate risk 150-299 ng/ml, and high risk ≥300 ng/ml.

Baseline, Hour 24, Hour 48
Kidney Injury Molecule-I Urine Level
Délai: Baseline, Hour 24, Hour 48

Kidney injury molecule-I urine level is used to detect kidney injury. Normal level is <1 ng/ml. Levels higher than normal indicate ischemic kidney injury.

Baseline, Hour 24, Hour 48
Kidney Injury Molecule-I Blood Level
Délai: Baseline, Hour 24, Hour 48

Kidney injury molecule-I blood level is used to detect kidney injury. Normal levels 0.42-2.0 ng/ml. Levels higher than normal indicate kidney injury. The higher the level the more severe.

Baseline, Hour 24, Hour 48
Soluble Receptor for Advanced Glycation End Product Level
Délai: Baseline, Hour 24, Hour 48

Soluble receptor for advanced glycation end product level is a marker of aging, hypertension and diabetes. Normal range is 647-1248 pg/ml. Levels higher than normal indicate risk for hypertension and diabetes.

Baseline, Hour 24, Hour 48
Angiopoietin-2 Level
Délai: Baseline, Hour 24, Hour 48, Hour 72

Angiopoietin-2 level is a marker of inflammation. Normal range is 1434-4141 pg/mL. Levels higher than normal indicate inflammation.

Baseline, Hour 24, Hour 48, Hour 72
Syndecan-1 Level
Délai: Baseline, Hour 24, Hour 48

Syndecan-1 level is a marker of disease severity in critically ill patients. Levels >20ng/ml indicate severe disease. The higher the level the more severe.

Baseline, Hour 24, Hour 48
Protein C Level
Délai: Baseline, Hour 24, Hour 48

Protein C level is an indicator of inflammation and thrombotic state. Normal level is <8 mg/L. Levels higher than normal indicate inflammation and thrombotic state. The higher the level the more severe.

Baseline, Hour 24, Hour 48
Neuron-Specific Enolase Level
Délai: Baseline, Hour 24, Hour 48

Neuron-specific enolase level is an indicator of brain injury. Normal range is 16-17 ug/L. Levels higher than normal indicate brain injury. The higher the level the more severe.

Baseline, Hour 24, Hour 48
S-100β Level
Délai: Baseline, Hour 24, Hour 48

S-100β level is indicator of brain injury. Normal range is 0.02-0.05 μg/dL. Levels higher than normal indicate brain injury. The higher the number the more severe.

Baseline, Hour 24, Hour 48
TNFα Level
Délai: Baseline, Hour 3, Hour 12, Hour 24, Hour 48

TNFα level is an indicator of systemic inflammation. Normal levels are 75 +/- 15 pg/ml. Levels higher than normal indicate inflammation. The higher the score the more severe.

Baseline, Hour 3, Hour 12, Hour 24, Hour 48
sTNFR1 Level
Délai: Baseline, Hour 3, Hour 12, Hour 24, Hour 48

sTNFR1 level is an indicator of systemic inflammation. Normal levels are <2.4 ng/ml. Levels higher than normal indicate inflammation. The higher the score the more severe.

Baseline, Hour 3, Hour 12, Hour 24, Hour 48
IL-6 Level
Délai: Baseline, Hour 3, Hour 12, Hour 24, Hour 48

IL-6 level is an indicator of systemic inflammation. Normal range is 0-43.5 pg/ml. Levels higher than normal indicate inflammation. The higher the score the more severe.

Baseline, Hour 3, Hour 12, Hour 24, Hour 48
sIL-6R Level
Délai: Baseline, Hour 3, Hour 12, Hour 24, Hour 48

sIL-6R level is an indicator of systemic inflammation. Normal range is 14-46 pg/ml. Levels higher than normal indicate inflammation. The higher the score the more severe.

Baseline, Hour 3, Hour 12, Hour 24, Hour 48
IL-8 Level
Délai: Baseline, Hour 3, Hour 12, Hour 24, Hour 48

IL-8 level is an indicator of systemic inflammation. Normal range is 0-66.1 pg/ml. Levels higher than normal indicate inflammation. The higher the score the more severe.

Baseline, Hour 3, Hour 12, Hour 24, Hour 48
IL-1β Level
Délai: Baseline, Hour 3, Hour 12, Hour 24, Hour 48

IL-1β level is an indicator of systemic inflammation. Normal range is 0.5-12 pg/ml. Levels higher than normal indicate inflammation. The higher the score the more severe.

Baseline, Hour 3, Hour 12, Hour 24, Hour 48
Interferon Gamma Level
Délai: Baseline, Hour 3, Hour 12, Hour 24, Hour 48

IFN-ɣ level is an indicator of systemic inflammation. Normal range is 0-8.6 pg/ml. Levels higher than normal indicate inflammation. The higher the score the more severe.

Baseline, Hour 3, Hour 12, Hour 24, Hour 48
IL12p70 Level
Délai: Baseline, Hour 3, Hour 12, Hour 24, Hour 48

IL12p70 level is an indicator of systemic inflammation. Normal range is 0-1.9 pg/ml. Levels higher than normal indicate inflammation. The higher the score the more severe.

Baseline, Hour 3, Hour 12, Hour 24, Hour 48
IL-17 Level
Délai: Baseline, Hour 3, Hour 12, Hour 24, Hour 48

IL-17 level is an indicator of systemic inflammation. Normal range is 0-1.4 pg/ml. Levels higher than normal indicate inflammation. The higher the score the more severe.

Baseline, Hour 3, Hour 12, Hour 24, Hour 48
MIP1-alpha Level
Délai: Baseline, Hour 3, Hour 12, Hour 24, Hour 48

MIP1-αlpha level is an indicator of systemic inflammation. Normal range is 0-208 pg/ml. Levels higher than normal indicate inflammation. The higher the score the more severe.

Baseline, Hour 3, Hour 12, Hour 24, Hour 48
MIP1-beta Level
Délai: Baseline, Hour 3, Hour 12, Hour 24, Hour 48

MIP1-beta level is an indicator of systemic inflammation. Normal range is 59-647 pg/ml. Levels higher than normal indicate inflammation. The higher the score the more severe.

Baseline, Hour 3, Hour 12, Hour 24, Hour 48
IP-10 Level
Délai: Baseline, Hour 3, Hour 12, Hour 24, Hour 48

IP-10 level is an indicator of systemic inflammation. Normal range is 4.8-9.8 pg/ml. Levels higher than normal indicate inflammation. The higher the score the more severe.

Baseline, Hour 3, Hour 12, Hour 24, Hour 48
IL-10 Level
Délai: Baseline, Hour 3, Hour 12, Hour 24, Hour 48

IL-10 level is an indicator of systemic inflammation. Normal range is 4.8-9.8 pg/ml. Levels higher than normal indicate inflammation. The higher the score the more severe.

Baseline, Hour 3, Hour 12, Hour 24, Hour 48
IL-1RA Level
Délai: Baseline, Hour 3, Hour 12, Hour 24, Hour 48

IL-1RA level is an indicator of systemic inflammation. Normal range is 100-300 ng/ml. Levels higher than normal indicate inflammation. The higher the score the more severe.

Baseline, Hour 3, Hour 12, Hour 24, Hour 48
IL-12p40 Level
Délai: Baseline, Hour 3, Hour 12, Hour 24, Hour 48

IL-12p40 level is an indicator of systemic inflammation. Normal range is 0.064-1000 pg/ml. Levels higher than normal indicate inflammation. The higher the score the more severe.

Baseline, Hour 3, Hour 12, Hour 24, Hour 48
C reactive protein (CRP) Level
Délai: Baseline, Hour 3, Hour 12, Hour 24, Hour 48

CRP level is an indicator of systemic inflammation. Normal range is 0-10 mg/dl. Levels higher than normal indicate inflammation. The higher the score the more severe.

Baseline, Hour 3, Hour 12, Hour 24, Hour 48
Procalcitonin Level
Délai: Baseline, Hour 3, Hour 12, Hour 24, Hour 48

Procalcitonin level is an indicator of systemic inflammation. Levels >0.25 mg/ml indicate inflammation and infection. The higher the score the more severe.

Baseline, Hour 3, Hour 12, Hour 24, Hour 48
Platelet Level
Délai: Baseline, Hour 3, Hour 12, Hour 24, Hour 48

Platelet level is an indicator of systemic inflammation and thrombocytosis. Normal range is 150000-450000 platelets per microliter. Levels higher than normal indicate inflammation and thrombocytosis. The higher the score the more severe.

Baseline, Hour 3, Hour 12, Hour 24, Hour 48
Absolute Neutrophil Count Level
Délai: Baseline, Hour 3, Hour 12, Hour 24, Hour 48

Absolute neutrophil count level is an indicator of inflammation and infection/sepsis. Normal range is 2500-7000 neutrophils per microliter. Levels higher than normal indicate inflammation, infection/sepsis. The higher the score the more severe.

Baseline, Hour 3, Hour 12, Hour 24, Hour 48
Absolute Granulocyte Count Level
Délai: Baseline, Hour 3, Hour 12, Hour 24, Hour 48

Absolute granulocyte count level is an indicator of inflammation and infection/sepsis. Normal range is 1500-8500 granulocytes per microliter. Levels higher than normal indicate inflammation, infection/sepsis. The higher the score the more severe.

Baseline, Hour 3, Hour 12, Hour 24, Hour 48
Absolute Lymphocytes Count Level
Délai: Baseline, Hour 3, Hour 12, Hour 24, Hour 48

Absolute lymphocyte count level is an indicator of inflammation and infection/sepsis. Normal range is 1000-4800 granulocytes per microliter. Levels higher than normal indicate inflammation, infection/sepsis. The higher the score the more severe.

Baseline, Hour 3, Hour 12, Hour 24, Hour 48
Neutrophil-Lymphocyte Ratio Level
Délai: Baseline, Hour 3, Hour 12, Hour 24, Hour 48

Neutrophil-lymphocyte ratio level is an indicator of inflammation and infection/sepsis or marrow malignancy. Normal range is 1-2. Levels higher than normal indicate inflammation, infection/sepsis, marrow malignancy. The higher the score the more severe.

Baseline, Hour 3, Hour 12, Hour 24, Hour 48
Angiotensin (1-7)
Délai: Baseline, Hour 3, Hour 12, Hour 24, Hour 48, Hour 72

Angiotensin (1-7) level as a measure of the renin-angiotensin-aldosterone system

Baseline, Hour 3, Hour 12, Hour 24, Hour 48, Hour 72
Plasma renin activity
Délai: baseline, hour 3, hour 12, hour 24, hour 48

levels at indicated timepoints

baseline, hour 3, hour 12, hour 24, hour 48
Prorenin
Délai: baseline, hour 3, hour 12, hour 24, hour 48

levels at indicated timepoints

baseline, hour 3, hour 12, hour 24, hour 48
Soluble prorenin receptor (sPRR)
Délai: baseline, hour 24, hour 48

levels at indicated timepoints

baseline, hour 24, hour 48
Aldosterone
Délai: baseline, hour 3, hour 12, hour 24, hour 48

levels at indicated timepoints

baseline, hour 3, hour 12, hour 24, hour 48
Intact Aogen
Délai: baseline, hour 24, hour 48

levels at indicated timepoints

baseline, hour 24, hour 48
ANG II
Délai: baseline, hour 3, hour 12, hour 24, hour 48, hour 72

levels at indicated timepoints

baseline, hour 3, hour 12, hour 24, hour 48, hour 72
Angiotensin-converting enzyme (ACE)
Délai: baseline, hour 24, hour 48

levels at indicated timepoints

baseline, hour 24, hour 48
Angiotensin-converting enzyme-2 (ACE2)
Délai: baseline, hour 24, hour 48

levels at indicated timepoints

baseline, hour 24, hour 48
Dipeptidyl peptidase 3 (DPP3)
Délai: baseline, hour 24, hour 48

levels at indicated timepoints

baseline, hour 24, hour 48
RNA Paxgene Bulk (Bulk RNA sequencing)
Délai: baseline, hour 24, hour 48

levels at indicated timepoints

baseline, hour 24, hour 48
Whole blood cryopreserved (scRNAsesq)
Délai: baseline, hour 24, hour 48

levels at indicated timepoints

baseline, hour 24, hour 48

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Patients with New Deep Venous Thrombosis
Délai: Day 7, Day 28

Number of patients with development of new deep venous thrombosis

Day 7, Day 28
Patients with New Pulmonary Embolism
Délai: Day 7, Day 28

Number of patients with development of new pulmonary embolism

Day 7, Day 28
Patients with New-Onset Atrial Fibrillation
Délai: Hour 72, day 28

Number of patients with new-onset atrial fibrillation

Hour 72, day 28
Patients with New-Onset Ventricular Arrhythmias
Délai: Hour 72, Day 7, Day 28

Number of patients with new-onset ventricular arrhythmias

Hour 72, Day 7, Day 28

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Ashish Khanna, MD, Atrium Health Wake Forest Baptist

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 novembre 2026

Achèvement primaire (Estimé)

30 septembre 2028

Achèvement de l'étude (Estimé)

7 octobre 2028

Dates d'inscription aux études

Première soumission

18 décembre 2024

Première soumission répondant aux critères de contrôle qualité

18 décembre 2024

Première publication (Réel)

24 décembre 2024

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

24 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

23 septembre 2026

Dernière vérification

1 juin 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

produit fabriqué et exporté des États-Unis.

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner